• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Tempus AI Inc.

    11/12/24 4:30:28 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology
    Get the next $TEM alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    United States

    Securities and Exchange Commission

    Washington, D.C. 20549

     

    Schedule 13G

     

    (Rule 13d-102)

     

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    (Amendment No. )*

     

    Tempus AI, Inc.

    (Name of Issuer)

     

    Class A Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    71535D106

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)
    ☐ Rule 13d-1(c)
    ☒ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 71535D106 Schedule 13G Page 1 of 6

     

    1

    Names of Reporting Persons

     

    Red Sky Ventures LLC

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

     

    3

    SEC Use Only

     

     

     
    4

    Citizenship or Place of Organization

     

    Delaware

     

    Number of Shares
    Beneficially Owned by
    Each Reporting Person
    With
    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    16,560,249

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    16,560,249

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    16,560,249

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11

    Percent of Class Represented by Amount in Row 9

     

    10.9%

    12

    Type of Reporting Person

     

    OO (Limited Liability Company)

     

     

     

     

    CUSIP No. 71535D106 Schedule 13G Page 2 of 6

     

    1

    Names of Reporting Persons

     

    Kimberly Jo Keywell

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

     

    3

    SEC Use Only

     

     

     
    4

    Citizenship or Place of Organization

     

    United States

     

    Number of Shares
    Beneficially Owned by
    Each Reporting Person
    With
    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    16,560,249

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    16,560,249

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    16,560,249

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11

    Percent of Class Represented by Amount in Row 9

     

    10.9%

    12

    Type of Reporting Person

     

    IN

     

     

     

     

    CUSIP No. 71535D106 Schedule 13G Page 3 of 6

     

    ITEM 1. (a)Name of Issuer:

     

    Tempus AI, Inc. (the “Issuer”).

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    600 West Chicago Avenue, Suite 510, Chicago, IL 60654

     

    ITEM 2. (a)Name of Person Filing:

     

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

     

    Red Sky Ventures LLC (“Red Sky”)

    Kimberly Jo Keywell

     

    (b)Address or Principal Business Office:

     

    The principal business address of each of the Reporting Persons is 1001 Green Bay Road, Suite 146, Winnetka, IL 60093.

     

    (c)Citizenship of each Reporting Person is:

     

    Red Sky is organized under the laws of the state of Delaware. Ms. Keywell is a citizen of the United States.

     

    (d)Title of Class of Securities:

     

    Class A common stock, par value $0.0001 per share (“Class A Common Stock”).

     

    (e)CUSIP Number:

     

    71535D106

     

    ITEM 3.  

     

    Not applicable.

     

     

     

     

    CUSIP No. 71535D106 Schedule 13G Page 4 of 6

     

    ITEM 4.Ownership.

     

    (a-c)

     

    The ownership information presented below represents beneficial ownership of shares of Class A Common Stock as of the date hereof, based upon 152,401,894 shares of Class A Common Stock outstanding as of November 4, 2024, as disclosed in the Issuer’s quarterly report on Form 10-Q, filed with the Securities and Exchange Commission on November 4, 2024.

     

    Reporting Person 

    Amount

    beneficially

    owned

      

    Percent

    of class:

       Sole
    power to
    vote or to
    direct
    the vote:
       Shared
    power to
    vote or to
    direct the
    vote:
      

    Sole power to dispose or to direct the disposition

    of:

      

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     
    Red Sky Ventures LLC   16,560,249    10.9%   0    16,560,249         0    16,560,249 
    Kimberly Jo Keywell   16,560,249    10.9%   0    16,560,249    0    16,560,249 

     

    Red Sky is the record holder of the shares of Class A Commoon Stock reported herein. Ms. Keywell is the sole member and manager of Red Sky. As a result, Ms. Keywell may be deemed to share beneficial ownership of the shares of Class A Common Stock directly held by Red Sky.

     

    ITEM 5.Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    ITEM 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    ITEM 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    ITEM 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    ITEM 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    ITEM 10.Certification.

     

    Not applicable.

     

     

     

     

    CUSIP No. 71535D106 Schedule 13G Page 5 of 6

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 12, 2024    
           
        Red Sky Ventures LLC
           
        By: /s/ Kimberly Jo Keywell
        Name: Kimberly Jo Keywell
        Title: President
           
        Kimberly Jo Keywell
         
        /s/ Kimberly Jo Keywell

     

     

     

     

    CUSIP No. 71535D106 Schedule 13G Page 6 of 6

     

    LIST OF EXHIBITS

     

    Exhibit No. Description
       
    99 Joint Filing Agreement.

     

     

     

    Get the next $TEM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TEM

    DatePrice TargetRatingAnalyst
    4/13/2026$35.00Underperform
    Jefferies
    4/13/2026$65.00Hold → Buy
    TD Cowen
    2/19/2026$100.00Outperform
    Mizuho
    2/17/2026$59.00Outperform
    Robert W. Baird
    12/2/2025$85.00Overweight
    Morgan Stanley
    10/21/2025$88.00Buy → Hold
    TD Cowen
    10/20/2025$110.00Buy
    Canaccord Genuity
    9/2/2025$90.00Buy
    H.C. Wainwright
    More analyst ratings

    $TEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tempus Ai, Inc. bought $2,739,181 worth of shares (320,267 units at $8.55), increasing direct ownership by 3% to 13,039,067 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Reporting)

    2/13/26 5:24:46 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Large owner Tempus Ai, Inc. exercised 9,218,800 in-the-money shares at a strike of $2.00 and bought $17,745,000 worth of shares (3,500,000 units at $5.07) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Reporting)

    8/20/24 4:17:55 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    SEC Filings

    View All

    SEC Form DEFA14A filed by Tempus AI Inc.

    DEFA14A - Tempus AI, Inc. (0001717115) (Filer)

    4/7/26 4:08:00 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form DEF 14A filed by Tempus AI Inc.

    DEF 14A - Tempus AI, Inc. (0001717115) (Filer)

    4/7/26 4:06:20 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Tempus AI Inc.

    SCHEDULE 13G/A - Tempus AI, Inc. (0001717115) (Subject)

    3/27/26 1:32:45 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acceptance of 31 abstracts—including one oral presentation—for the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17–22 in San Diego. "The research that Tempus is presenting at this year's AACR annual meeting underscores the scale and real-world impact of Tempus' multimodal dataset and AI-enabled diagnostic solutions," said Kate Sasser, PhD, Chief Scientific Officer at Tempus. "Across these studies, our researchers are uncovering clinically relevant insights that not only deepen our understanding of tumor biology, but also

    4/14/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Launches Automated "Active Follow-Up" Service to Support Guideline-Concordant Care

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of an automated clinical update service designed to support guideline-concordant care by placing patients on an "active follow-up" track. This integrated workflow provides clinicians with ongoing therapy monitoring and context-aware notifications seamlessly delivered through Hub, Tempus' secure, AI-enabled physician portal. Because NCCN guidelines, FDA approvals, and patient context can all evolve rapidly, an initial genomic report can quickly become outdated relative to a patient's ongoing treatment journey. Tempus is addressing this challenge by automat

    4/13/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (NASDAQ:GILD) aimed at building and advancing Gilead's oncology pipeline. To date, Gilead has leveraged Tempus' extensive repository of de-identified multimodal data to inform a range of oncology R&D initiatives, including trial design, indication selection, biomarker strategy, health outcomes analysis and clinical real world evidence. The expanded agreement provides Gilead with enterprise-wide access to Tempus' AI-driven Lens platform, unlocking access to broader datasets across multiple indications a

    4/9/26 8:30:00 AM ET
    $GILD
    $TEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Tempus AI with a new price target

    Jefferies initiated coverage of Tempus AI with a rating of Underperform and set a new price target of $35.00

    4/13/26 9:01:23 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI upgraded by TD Cowen with a new price target

    TD Cowen upgraded Tempus AI from Hold to Buy and set a new price target of $65.00

    4/13/26 8:40:42 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Mizuho initiated coverage on Tempus AI with a new price target

    Mizuho initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $100.00

    2/19/26 7:52:33 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lefkofsky Eric P

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    3/27/26 9:46:17 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Director Epstein David R sold $12,672 worth of shares (250 units at $50.69), decreasing direct ownership by 0.96% to 25,801 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    3/4/26 4:30:27 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Chief Financial Officer Rogers James William sold $578,576 worth of shares (11,414 units at $50.69), decreasing direct ownership by 8% to 127,248 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    3/4/26 4:30:25 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Leadership Updates

    Live Leadership Updates

    View All

    FDA Clearance Sets Stage for U.S. Commercialization of eyonis® LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.

    Oran Muduroglu, proven medical imaging entrepreneur, to lead U.S. launch of eyonis® LCS Established U.S. commercial and clinical infrastructure combined with Medicare reimbursement pathway already in place to support expansion Active discussions underway to establish key clinical partnerships to support broad access across U.S. lung cancer screening programs Webcasts will be held on February 26, 2026, to discuss the Company's recent achievements and upcoming milestones for eyonis® LCS deployment in the U.S. Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218440005/en/Oran Muduroglu Appointed Presi

    2/18/26 11:45:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention Center in National Harbor, Maryland. "We're excited to join the oncology community at this year's meeting and highlight our latest research and progress in advancing the immuno-oncology field," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "Our latest findings demonstrate the potential of integrated, data-driven approaches to refine biomarkers, im

    11/5/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Financials

    Live finance-specific insights

    View All

    Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4652845 United States - New York: (646) 307-1963 USA & Canada - Toll-Free: (800) 715-9871 Live Webcast: https://edge.media-

    2/10/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus to Report Third Quarter 2025 Financial Results on November 4

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 5436492 USA & Canada: Toll-Free (800) 715-9871 United States: Toll (646) 307-1963 Live Webcast: https://edge.media-server.com/mmc/p/vg3azega A

    10/21/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Announces the Acquisition of Paige

    Paige's strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology, allowin

    8/22/25 9:20:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 5:00:02 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 4:30:28 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13D/A filed by Tempus AI Inc.

    SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

    8/20/24 4:27:51 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology